Sexual Differences in response to Mid- or Low-Premixed Insulin Analogue in Patients with Type 2 Diabetes

Table 3

Glycemic variations in male and female patients receiving low- and mid-mixed insulin analogues.

Items	Male (52)			Female (50)
	Asp 30	Lis 50		Asp 30	Lis 50
	25 (10.3, 38.8)	19 (6, 31.3)	0.14	34.5 (15, 50)	22 (10.8, 46.3)	0.28
	0 (0, 4.8)	0 (0, 0)	0.01	0 (0, 0)	0 (0, 0)	0.86
Duration 3.9-10			0.01			0.27
	0.5 (0.1, 0.8)	0.3 (0.1, 0.5)	0.13	0.7 (0.2, 1.3)	0.5 (0.1, 1.3)	0.35
	0 (0, 0)	0 (0, 0)	0.44	0 (0, 0)	0 (0, 0)	0.56
AUC 3.9-10			0.16			0.42
24 hr MG			0.1			0.35
MAGE			0.71			0.65
CV%			0.97			0.98
SDMG			0.45			0.62

, male asp30 vs. male lis50. : time spent in glucose levels above 10.0 mmol/L (%); : time spent in glucose levels less than 3.9 mmol/L (%); : the incremental area under curve of glucose > 10.0 mmol/L (); : the incremental area over curve of plasma (); AUC 3.9-10: the incremental area under the curve of glucose levels between 3.9 and 10 mmol/L; 24 hr MG: 24 hr mean glucose (mmol/L); MAGE: mean amplitude of glycemic excursions (mmol/L); CV%: the coefficient of variation; SDMG: standard deviation (mmol/L).